MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
John Mascarenhas(Tisch Hospital), Srđan Verstovšek(Unknown), Suresh Bobba(Constellation Pharmaceuticals (United States)), Jessica Christo(Constellation Pharmaceuticals (United States)), Adrian M. Senderowicz, James Shao(Sarepta Therapeutics (United States)), Katarina Luptakova(Tesaro (United States)), Jennifer A. Mertz(Constellation Pharmaceuticals (United States)), Claire Harrison(National Health Service), Jing Wang(Sun Yat-sen University), Patrick Trojer(Morpho (United States)), Jeffrey S. Humphrey, Gozde Colak(Morpho (United States))
Cited by 21
Related Papers
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
|Annals of Neurology|2015|502
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
|Blood|2006|468